What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier interventions, and smarter diagnostics.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002058. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Manipulating Hepcidin in Polycythemia Vera https://pubmed.ncbi.nlm.nih.gov/37383006/

Role of ASXL1 and TP53 Mutations in the Molecular Classification and Prognosis of Acute Myeloid Leukemias With Myelodysplasia-Related Changes https://pubmed.ncbi.nlm.nih.gov/25860933/

Cryptic KMT2A::AFDN Fusion Due to AFDN Insertion Into KMT2A in a Patient With Acute Monoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/40149468/ 

8p11 Myeloproliferative Syndrome: A Review https://pubmed.ncbi.nlm.nih.gov/20226962/

What's Next? Clinical Trials in Myelofibrosis https://www.medscape.com/viewarticle/1002053

Artificial Intelligence-Based Morphological Fingerprinting of Megakaryocytes: A New Tool for Assessing Disease in MPN Patients https://pubmed.ncbi.nlm.nih.gov/32706893/

Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies https://pubmed.ncbi.nlm.nih.gov/37290996/

The Telomerase Inhibitor Imetelstat Differentially Targets JAK2V617F Versus CALR Mutant Myeloproliferative Neoplasm Cells and Inhibits JAK-STAT Signaling https://pubmed.ncbi.nlm.nih.gov/37941547/

A Novel Application of XPO1 Inhibition for the Treatment of Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/40454401/

BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/36416118/

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial https://pubmed.ncbi.nlm.nih.gov/37126762/

Center for International Blood & Marrow Transplant Research (CIBMTR) https://cibmtr.org/

Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study https://pubmed.ncbi.nlm.nih.gov/38916866/ 

Clearance of Driver Mutations After Transplantation for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/39778169/ 

Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment https://ashpublications.org/blood/article/144/Supplement%201/871/531067/Development-of-a-First-in-Class-CAR-T-Therapy